Remarkable advances have been made in the field of cellular therapy in recent years, including the Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T cell therapies as standard of care for the treatment of relapsed or refractory CD19+ malignancies including B cell acute lymphoblastic leukemia (B-ALL) (1), diffuse large B-cell lymphoma (DLBCL) (2), and mantle cell lymphoma (3). Here, CD19 is linked to diffuse large B-cell lymphoma.